Danish pharmaceutical company Novo Nordisk has partnered with Amazon Web Services (AWS) to integrate artificial intelligence into its drug discovery process. The collaboration will see AWS provide AI tools for identifying potential targets and designing therapies, as well as streamlining research workflows. As a result of the partnership, AWS will become Novo Nordisk's preferred cloud provider and strategic AI partner. The companies have also established a joint innovation hub in London. This partnership has the potential to accelerate the development of new treatments and improve the efficiency of the pharmaceutical industry.